Argenx
Established: 2008
Country: Netherlands
Region: Breda
Investors: EQT Life Sciences, BioGeneration Ventures, Erasmus MC Biomedical Fund, Forbion, Thuja Capital, KBC Private Equity, VIB, Omnes Capital, Seventure, OrbiMed Advisors, The Institute for the Promotion of Innovation by Science and Technology in Flanders, ZAI Lab Limited, PMV
Founded in Breda in the Netherlands, Argenx is developing treatments to combat rare and severe auto-immune conditions. With venture capital support, the company pursued its aim of being first-in-class by collaborating closely with academic institutions, as well as strategic and industry partners, to identify novel targets, track disease pathways, and create therapeutic antibodies.
Argenx’s leading treatment Efgartigimod (VYVGART in the US) is helping patients with myasthenia gravis, a rare neuromuscular disease that can make speaking, eating and other simple physical actions more difficult for sufferers. The research programme has also resulted in the development of candidates that can stimulate the body’s immune response to combat cancer, with Argenx partnering with US biotech AbbVie on development.
Tim Van Hauwermeiren and the success story behind argenx (Video – 10:06)
$115m
raised in 2017 Nasdaq listing
€42m
raised from VC in pre-IPO funding rounds
650
staff in 2021, a five-fold increase
Key achievements
US approval for VYVGART, helping sufferers of neuromuscular condition myasthenia gravis
Raised $115m in 2017 Nasdaq listing, 50% above initial target1
Increased market cap from €132m at 2014 Euronext IPO2 to over €21bn in 20223
Funding history
Raised €42m from VC in pre-IPO funding rounds4
Raised over $3.6bn in 2014 IPO and subsequent placements5
Employment impact
More than five-fold increase in workforce to 650 in four years to 20216
Find out more
1. https://www.fiercebiotech.com/biotech/argenx-ipo-haul-tops-out-at-115m-50-above-initial-goal
2. https://www.lspvc.com/news/argen-x-raises-40-million-in-successful-initial-public-offering-on-euronext-brussels.html
3. https://www.bloomberg.com/quote/ARGX:BB?sref=KaVRqOin
4. https://www.argenx.com/news/argen-x-raises-eu95-million-put-simple-antibodytm-platform-work; https://www.argenx.com/news/argen-x-raises-eur-5-million-pmv-extension-eur-325-million-series-b; https://www.argenx.com/news/argen-x-raises-eur-275-million-usd-37-million-oversubscribed-series-b-round
5. Preqin
6. https://www.macrotrends.net/stocks/charts/ARGX/argenex-se/number-of-employees#:~:text=Argenex%20SE%20total%20number%20of%20employees%20in%202020%20was%20336,a%2079.05%25%20increase%20from%202018.
Investors
